Solid Biosciences INC Form 4 insider transactions

Solid Biosciences Inc. Director Lynne Marie Sullivan was granted 77,500 stock options with an exercise price of $4.58, aligning her interests with shareholder value.

Director Ian F. Smith reports acquisition of Solid Biosciences common stock through vesting of restricted stock units.

Director Clare Kahn of Solid Biosciences Inc. reports the acquisition and disposal of common stock on March 11, 2025.

Bain Capital Life Sciences entities increased their investment in Solid Biosciences through a recent underwritten public offering, acquiring common stock and pre-funded warrants.

Perceptive Advisors and related entities acquired 5,000,000 shares of Solid Biosciences at $4.03 per share, increasing their beneficial ownership.

RA Capital Management and related parties acquired pre-funded warrants to purchase 3,722,085 shares of Solid Biosciences Inc. common stock.

Adage Capital Management, a 10% owner of Solid Biosciences, sold 252,545 shares of common stock at an average price of $7.56 on February 18, 2025.

Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences Inc., reports the vesting and subsequent sale of restricted stock units to cover withholding taxes.

Gabriel Brooks, Chief Medical Officer of Solid Biosciences, reports the acquisition and disposal of common stock and restricted stock units.

Kevin Tan, CFO & Treasurer of Solid Biosciences Inc., reports the acquisition and disposal of common stock and restricted stock units.

David Howton, COO of Solid Biosciences, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Paul Herzich, Chief Technology Officer of Solid Biosciences Inc., reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Alexander Cumbo, CEO of Solid Biosciences, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Director Ilan Ganot reports acquisition and disposal of Solid Biosciences Inc. stock, including transactions by his wife to cover withholding taxes.

Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences Inc., was granted 110,500 restricted stock units (RSUs) on January 31, 2025, vesting over four years.

Paul Herzich, Chief Technology Officer of Solid Biosciences Inc., reports the acquisition of common stock through an employee stock purchase plan and the grant of restricted stock units.

Director Ilan Ganot reports the acquisition of 60,000 Restricted Stock Units (RSUs) in Solid Biosciences Inc.

Kevin Tan, CFO & Treasurer of Solid Biosciences Inc., reports the acquisition of 132,300 restricted stock units (RSUs) on January 31, 2025, according to a Form 4 filing with the SEC.

Gabriel Brooks, Chief Medical Officer of Solid Biosciences, reports acquisition of common stock through an employee stock purchase plan and grant of restricted stock units.

David Howton, Chief Operating Officer of Solid Biosciences Inc., was granted 169,100 restricted stock units (RSUs) on January 31, 2025, vesting over four years.

Alexander Cumbo, CEO of Solid Biosciences, reports the acquisition of common stock through an employee stock purchase plan and the grant of restricted stock units.

Director Ilan Ganot reports acquisition and disposition of Solid Biosciences Inc. stock and restricted stock units, including sales to cover withholding taxes.

Solid Biosciences CFO Kevin Tan reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Director Ilan Ganot of Solid Biosciences Inc. reports the acquisition and disposal of company stock and restricted stock units.

Director Ian F. Smith of Solid Biosciences Inc. reports the acquisition of common stock and stock options, along with the vesting of restricted stock units.

Solid Biosciences' Chief Regulatory Officer, Jessie Hanrahan, reported the acquisition of 11,862 shares through restricted stock unit vesting and the sale of 4,610 shares to cover withholding taxes.

Solid Biosciences CEO Alexander Cumbo acquired shares through restricted stock units and sold shares to cover withholding taxes.

Solid Biosciences' Chief Operating Officer, David Howton, reported the acquisition of shares through restricted stock unit vesting and the sale of shares to cover withholding taxes.

Solid Biosciences' Chief Technology Officer, Paul Herzich, reported the acquisition of 7,239 shares through restricted stock units and the sale of 2,777 shares to cover withholding taxes.

Solid Biosciences director Adam Stone was granted 34,400 stock options on June 11, 2024, which vest within one year or upon a change of control.